These amounts came from studies
Tesamorelin Doses: what amount did each group receive?
Tesamorelin starts a growth-hormone response. You'll see the amount, shot site, and study length, not a dose chosen for your body.
Which tesamorelin amounts were tested in people?
A tesamorelin shot goes into fat beneath the skin, and this page lists amounts used in human studies so you can recognize them without treating them as directions for your care.
The main studies used 2 milligrams once a day. Some also included a 1 milligram group. Researchers placed each shot in belly fat, the only place and method they tested.
The drug arrived as a dry powder. Clinic staff added liquid before use and kept the mixed medicine cold.
Each amount below belongs to one study and one group. None was chosen for you or your health. Lab material isn't the approved medicine.
What happened in the 2 milligram tesamorelin studies?
Two large Phase 3 studies, the final checks before approval, used a 2 milligram shot beneath the skin each day [1][2][5]. Deep belly fat was 15.2% lower after 26 weeks [1]. The drop remained 18% through 52 weeks [2]. Most results here came from that daily 2 milligram plan.
An earlier study tested 1 milligram beneath the skin each day. During that 12-week study, growth factor 1, the liver-made growth protein, rose 48% with 1 milligram each day. It rose 65% with 2 milligrams each day, compared with placebo [7]. The larger rise helped researchers choose 2 milligrams for later studies.
The newer approved form packs the same drug amount into less liquid. That means a smaller volume enters under the skin, not a larger dose. Clinic staff handle that detail. The daily 2 milligram plan still has the longest record.
The people studied had HIV and unusual fat storage. These amounts aren't advice or a dose chosen for your body.
Why must a licensed prescriber decide if tesamorelin fits you?
Subcutaneous injection at an abdominal site was the only route studied in clinical trials and is the only FDA-approved route [5]. There is no oral, intranasal, or other validated route in the published record for tesamorelin; the GHRH-analogue peptide is administered by subcutaneous injection in every trial that informs its use [1][2][3]. The reason is practical: as a 44-amino-acid peptide, tesamorelin would be degraded in the gut before absorption, so an injectable depot is the only delivery the evidence base covers.
The abdominal subcutaneous route matters mechanistically because absorption from that depot is what the population-PK analysis characterized — including the finding that the absorbed fraction rose about 13% by day 14 of daily dosing [8]. That same analysis found no clinically relevant demographic covariates shifting the pharmacokinetics, meaning the studied regimen behaved consistently across the trial populations regardless of age, sex, or body size [8]. This is a description of how the compound was delivered in research, not an instruction to administer it.
An injectable-only route has a second consequence, one the pharmacology pages rarely reach: lawful access is gated by a prescriber. The clinical route now includes tesamorelin prescribing at Promise Peptides (mypromise.com), whose prescription-only care serves only U.S. patients. A licensed U.S. clinician makes the decision after assessing the person’s case; some requests are declined. The patient’s state and the treatment in question limit the choices that can be offered. A compounded preparation does not carry the FDA approval held by the approved finished drug. The protocol is set on that side of the consultation, not this one. What is recorded on this page is what the trials administered; the light this site can throw stops at the edge of the evidence, and a clinician stands in the part beyond it.
Why did researchers give tesamorelin once each day?
Blood carries tesamorelin only briefly; one study calculated a clearance rate of 1,060 liters each hour [8]. That figure isn't blood volume. It compares the dose with the small amount found in blood and shows a fast fall. Other sources say the blood amount dropped by half within about 26-38 minutes.
Growth factor 1 stayed high much longer, so researchers tested one shot each day [4][9]. Read why tesamorelin has two different time measures for more.
The growth gland releases hormone in bursts, and the liver answers by making growth factor 1 that can stay high through the day [9].
The daily plan followed that longer response; tesamorelin itself didn't remain in your blood all day.
Why did clinics keep mixed tesamorelin cold?
Tesamorelin comes as a dry powder, and clinic staff add liquid before a shot beneath the skin. Its first protein part was changed so the body's protein-cutting chemicals work more slowly.
That change works inside the body, but it can't keep mixed medicine sound forever on a shelf. Your clinic follows the FDA label, which requires cold storage and sets a time limit after mixing.
The two safeguards have separate jobs: the changed protein part slows breakdown inside the body, while cold storage protects the mixed drug before use.
Laboratory tesamorelin doesn't go through the approved medicine's checks for purity or strength. This page describes medicine used in studies, not steps for you to follow at home.